Two-Way: A Novel Method for Identifying the Anatomy During Uniportal Thoracoscopic Segmentectomy

Sunyin Rao(Kunming Medical University), Yunchao Huang(North China University of Water Resources and Electric Power), Jichen Yang(Kunming Medical University), Qingling Sun(Shandong University of Science and Technology), Run Cao(Kunming Medical University), Wei Wang(Fujian Medical University), Lianhua Ye(Kunming Medical University), Shouyong Xiao(Kunming Medical University), Li Min(Kunming Medical University), Cun Xin(Kunming Medical University)
The Annals of Thoracic Surgery
May 31, 2020
10.1016/j.athoracsur.2020.04.041
Cited by 1

Related Papers

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: Overall design and results from a multicenter retrospective epidemiologic survey
|Lung Cancer|2018|134
<scp>C</scp>hina national lung cancer screening guideline with low‐dose computed tomography (2015 version)
|Thoracic Cancer|2015|89
LUX-Lung 6: A randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M+) advanced adenocarcinoma of the lung.
|Journal of Clinical Oncology|2013|83